• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

FR DATE:01/13/2003

[Federal Register: January 13, 2003 (Volume 68, Number 8)]

[Notices]               

[Page 1619]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr13ja03-62]                         





-----------------------------------------------------------------------





DEPARTMENT OF HEALTH AND HUMAN SERVICES





Food and Drug Administration





[Docket No. 01N-0566]





 

Renee Peugeot; Debarment Order





AGENCY: Food and Drug Administration, HHS.





ACTION: Notice.





-----------------------------------------------------------------------





SUMMARY: The Food and Drug Administration (FDA) is issuing an order 

under the Federal Food, Drug, and Cosmetic Act (the act) permanently 

debarring Renee Peugeot from providing services in any capacity to a 

person that has an approved or pending drug product application. FDA 

bases this order on a finding that Ms. Peugeot was convicted of a 

felony under Federal law for conduct relating to the development or 

approval, including the process for development or approval, of a drug 

product. Ms. Peugeot failed to request a hearing and, therefore, has 

waived her opportunity for a hearing concerning this action.





DATES: This order is effective January 13, 2003.





ADDRESSES: Submit applications for termination of debarment to the 

Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 

Fishers Lane, rm. 1061, Rockville, MD 20852.





FOR FURTHER INFORMATION CONTACT: Nicole K. Mueller, Center for Drug 

Evaluation and Research (HFD-7), Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 301-594-2041.





SUPPLEMENTARY INFORMATION:





I. Background





    On August 31, 2000, the U.S. District Court for the Northern 

District of Alabama entered judgment against Ms. Peugeot for two counts 

of making false statements to an agency of the United States, two 

counts of mail fraud, and one count of conspiracy to commit offenses 

against the United States, Federal felony offenses under 18 U.S.C. 2, 

1001, 1341, and 371, respectively. These offenses were committed as 

part of the development of a new drug for which Ms. Peugeot was 

conducting efficacy trials.

    As a result of this conviction, FDA served Ms. Peugeot by certified 

mail on May 8, 2002, a notice proposing to permanently debar Ms. 

Peugeot from providing services in any capacity to a person that has an 

approved or pending drug product application. The proposal also offered 

Ms. Peugeot an opportunity for a hearing on the proposal. The proposal 

was based on a finding, under section 306(a)(2)(A) of the act (21 

U.S.C. 335a(a)(2)(A)), that Ms. Peugeot was convicted of a felony under 

Federal law for conduct relating to the development or approval, 

including the process for development or approval, of a drug product. 

Ms. Peugeot was provided 30 days to file objections and request a 

hearing. Ms. Peugeot did not request a hearing. Her failure to request 

a hearing constitutes a waiver of her opportunity for a hearing and a 

waiver of any contentions concerning her debarment.





II. Findings and Order





    Therefore, the Director, Center for Drug Evaluation and Research, 

under section 306(a)(2)(A) of the act, and under authority delegated to 

her (21 CFR 5.34), finds that Ms. Renee Peugeot has been convicted of a 

felony under Federal law for conduct relating to the development or 

approval, including the process for development or approval, of a drug 

product.

    As a result of the foregoing finding, Ms. Renee Peugeot is 

permanently debarred from providing services in any capacity to a 

person with an approved or pending drug product application under 

section 505, 512, or 802 of the act (21 U.S.C. 355, 360b, or 382), or 

under section 351 of the Public Health Service Act (42 U.S.C. 262), 

(see sections 306(c)(1)(B) and (c)(2)(A)(ii) and 201(dd) of the act (21 

U.S.C. 321(dd))). Any person with an approved or pending drug product 

application who knowingly uses the services of Ms. Peugeot, in any 

capacity, during her period of debarment, will be subject to civil 

money penalties (section 307(a)(6) of the act (21 U.S.C. 335b(a)(6))). 

If Ms. Peugeot, during her period of debarment, provides services in 

any capacity to a person with an approved or pending drug product 

application, she will be subject to civil money penalties (section 

307(a)(7) of the act). In addition, FDA will not accept or review any 

abbreviated new drug applications submitted by or with the assistance 

of Ms. Peugeot during her period of debarment.

    Any application by Ms. Peugeot for termination of debarment under 

section 306(d)(4) of the act should be identified with Docket No. 01N-

0566 and sent to the Dockets Management Branch (see ADDRESSES). All 

such submissions are to be filed in four copies. The public 

availability of information in these submissions is governed by 21 CFR 

10.20(j). Publicly available submissions may be seen in the Dockets 

Management Branch between 9 a.m. and 4 p.m., Monday through Friday.





    Dated: December 23, 2002.

Janet Woodcock,

Director, Center for Drug Evaluation and Research.

[FR Doc. 03-663 Filed 1-10-03; 8:45 am]



BILLING CODE 4160-01-S